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Fibrinopeptide A is a small. short-lived polypeptide liberated 
from fibrinogen by the action of thrombin. Elevated plasma 
levels can be detected in patients with unstable angina (1) 
and acute myocardial infarction (2). Persistently elevated 
levels in unstable angina (3) or after thrombolytic therapy for 
acute infarction (4) indicate ongoing thrombotic activity and 
patients with this finding tend to have a poorer prognosis 
than that of patients whose initially high levels normalize. 
Variant angina versus unstable angina. In this issue of the 
Journal, Irie et al. (5) report that fibrinopeptide A levels are 
also increased after episodes of variant angina. Elevations 
were documented after both spontaneous attacks and those 
provoked by hyperventilation. However, when hyperventi- 
lation did not induce an attack, fibrinopeptide A levels did 
not increase. Similarly, after exercise-induced angina in 
another group of patients with stable effort angina, fibrin- 
opeptide A was not generated. 
Is this phenomenon clinical!\l relevant? Myocardial in- 
farction is a frequent complication during the active phase of 
variant angina (6.7). Treatment with calcium channel block- 
ers not only prevents attacks but also appears to reduce the 
incidence of myocardial infarction (7). In patients whose 
Although myocardial ischemic episodes are associated 
with fibrinopeptide A release in both variant and unstable 
angina, the underlying pathophysiologic mechanisms differ 
in the two conditions. In unstable angina. thrombosis occurs 
primarily on a complicated atherosclerotic plaque; ischemia 
develops downstream as a consequence of intermittent sub- 
total occlusion. Irie et al. (5) suggest that a different pattern 
occurs in variant angina: severe vasospasm of a coronary 
artery causes sluggish flow or stasis downstream, with 
thrombosis and fibrinopeptide A release occurring second- 
arily. 
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attacks continue despite antianginal therapy, concomitant 
treatment with heparin or oral anticoagulant agents would 
seem to be a logical way to prevent coronary thrombosis 
downstream from the site of coronary spasm. These drugs 
are not commonly used in variant angina and their potential 
benefit in this form of angina remains speculative. 
In contrast, heparin definitely prevents myocardial infarc- 
tion in the active phase of unstable angina (8). When 
myocardial infarction occurs despite treatment with heparin, 
it is likely to be of the non-Q wave variety and smaller than 
that in patients who did not receive heparin (9). Thrombin 
appears to be an important mediator of the thrombotic 
process at the complicated atherosclerotic plaque, and the 
antithrombin action of heparin may explain its beneficial 
effect. 
Variations in coronary tone undoubtedly contribute to the 
decrease in regional Row that causes ischemia in unstable 
angina; however, coronary spasm does not play the major 
role in unstable angina that it does in variant angina. Exper- 
imentally, platelet deposition on a complex arterial lesion 
and vasoconstriction are interrelated (10). Yet, clinically. the 
distinction between unstable and variant angina can be 
important. For example. therapies such as propranolol (I 1) 
and coronary angioplasty (12) are much less effective in 
variant than in unstable angina. 
Treating coronary thrombosis with thrombolysis reduces 
mortality. The current appropriate enthusiasm for throm- 
bolytic therapy reduces interest in other potential mecha- 
nisms that may be involved in the pathogenesis of myocar- 
dial infarction. 
Coronary spasm and mgocardial infarction. lrie et al. (5) 
allude to the possibility that coronary vasospasm is one of 
the primary factors in the pathogenesis of myocardial infarc- 
tion. This notion was in vogue a decade ago, but the high 
prevalence of thrombus without spasm at angiography early 
after the onset of infarction has made this theory less 
attractive. The finding of Irie et al. that spasm can induce 
thrombosis. or at least fibrinopeptide A release, supports the 
concept that coronary spasm causes myocardial infarction. 
The circumstantial evidence that coronary spasm is respon- 
sible for infarction is very convincing for patients with 
variant angina. much less so for the overwhelming majority 
of patient> with infarction. 
Fibrinopeptide A as a diagnostic test. Measuring tihrin- 
opeptide A levels in patients with recent chest pain, or to 
assess prognosis in unstable angina or after thromholysis, 
could he clinically helpful. However, elevated levels are not 
specific for infarction, and care must he taken in sampling or 
levels will be spuriously high. Other diagnostic tests or 
prognostic indicators may provide better information. The 
ultimate clinical utility of measuring fibrinopeptide A or 
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other markers of platelet and thrombin activation remains to 
be determined by further research. 
Investigation of acute coronary syndromes has been 
accelerated by the availability of laboratory methods to 
assess platelet and thrombin activity. These techniques 
permit the assay of minute amounts of biologic material 
released by the activation of platelets and the coagulation 
system and have enhanced our understanding of platelet and 
thrombin participation in these pathophysiologic processes. 
Specifically, fibrinopeptide A has proved to be a useful clue 
that has advanced our understanding of different coronary 
syndromes. 
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